-HERV-K (HML-2) expression correlates with disease progression, lymph node metastasis, and reduced overall survival.-HERV-K env protein shows promise as a therapeutic target in immune-mediated therapies. Anti-HERV-K monoclonal antibodies (mAbs) and HERV-K env-specific CAR-T cells have effectively reduced tumor growth [60,122]. This evidence concerns the gene ERVW-1 and metastatic malignant neoplasm in the lymph nodes.